Meningococcal vaccine GSK 134612

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, MeningococcalMeningococcal Infection

Phase 2

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

CompletedNCT01165242

GlaxoSmithKlineInfections, Meningococcal

Start: 2010-08-19End: 2011-07-29Updated: 2018-06-26

Phase 3

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years

CompletedNCT01235975

GlaxoSmithKlineInfections, Meningococcal

Start: 2010-11-30End: 2011-08-03Updated: 2018-08-20

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers

CompletedNCT01340898

GlaxoSmithKlineMeningococcal Infection

Start: 2012-01-27End: 2015-10-19Updated: 2019-08-06

Related Papers

Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.

2018-05-1811 citations

Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age

Journal of the Pediatric Infectious Diseases Society2013-10-1728 citations